Option Care Health's (OPCH) "Outperform" Rating Reaffirmed at Barrington Research

Option Care Health (NASDAQ:OPCH - Get Free Report)'s stock had its "outperform" rating reaffirmed by equities research analysts at Barrington Research in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $38.00 target price on the stock. Barrington Research's price objective would suggest a potential upside of 26.12% from the stock's current price.

A number of other analysts have also weighed in on OPCH. UBS Group upgraded shares of Option Care Health from a "neutral" rating to a "buy" rating and upped their target price for the stock from $38.00 to $40.00 in a research note on Wednesday, April 30th. JMP Securities reaffirmed a "market outperform" rating and issued a $36.00 price target on shares of Option Care Health in a report on Wednesday, June 18th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $35.50.

Option Care Health Trading Down 1.2%

NASDAQ OPCH traded down $0.36 during trading hours on Thursday, reaching $30.13. The company had a trading volume of 35,739 shares, compared to its average volume of 1,849,974. The stock has a 50-day moving average of $31.86 and a 200 day moving average of $31.31. Option Care Health has a 1-year low of $21.39 and a 1-year high of $35.53. The company has a current ratio of 1.54, a quick ratio of 1.02 and a debt-to-equity ratio of 0.82. The stock has a market capitalization of $4.93 billion, a P/E ratio of 24.30, a price-to-earnings-growth ratio of 1.85 and a beta of 0.73.

Option Care Health (NASDAQ:OPCH - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $0.40 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.36 by $0.04. The company had revenue of $1.33 billion for the quarter, compared to analyst estimates of $1.26 billion. Option Care Health had a net margin of 4.12% and a return on equity of 16.90%. The business's revenue for the quarter was up 16.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.26 earnings per share. As a group, research analysts anticipate that Option Care Health will post 1.22 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Option Care Health

Hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Option Care Health by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 19,315,421 shares of the company's stock worth $448,118,000 after purchasing an additional 75,313 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Option Care Health by 84.6% during the fourth quarter. Wellington Management Group LLP now owns 18,325,123 shares of the company's stock worth $425,143,000 after purchasing an additional 8,400,208 shares during the period. Fuller & Thaler Asset Management Inc. lifted its holdings in shares of Option Care Health by 30.8% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 4,204,481 shares of the company's stock worth $146,947,000 after purchasing an additional 989,048 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Option Care Health by 17.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,988,051 shares of the company's stock valued at $92,518,000 after acquiring an additional 591,042 shares during the period. Finally, Durable Capital Partners LP acquired a new stake in Option Care Health in the first quarter valued at $122,905,000. 98.05% of the stock is currently owned by hedge funds and other institutional investors.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.